Demetrix is a company which developed cannabinoid fermentation through yeast. The potential of fermenting yeast to produce rare cannabinoids such as CBG, CBC, CBN at ~1% of the cost is an immense breakthrough in cannabis science.
However, the company is defunct and no longer active. I see incredible potential in resurrecting the company.
Here is an initial research prompt:
Demetrix was a biotechnology company established in 2015 to commercialize cannabinoid biosynthesis. The company was built on an exclusive technology license from the University of California, Berkeley. The foundational research was led by co-founder Dr. Jay Keasling, a UC Berkeley professor and Scientific Director of the Novo Nordisk Foundation Center for Biosustainability.
Despite securing significant venture capital and establishing supply partnerships, Demetrix quietly shut down operations in 2024.
The Science: Brewing Cannabinoids
Demetrix utilized a specialized fermentation process, similar to brewing beer, to produce cannabinoids. The company genetically modified standard brewer’s yeast (Saccharomyces cerevisiae) by inserting more than a dozen cannabis genes into the yeast’s DNA.
- The Biosynthetic Pathway: The genetically altered yeast consumed simple sugars, such as galactose, to produce olivetolic acid.
- The “Mother” Cannabinoid: The yeast converted this acid into cannabigerolic acid (CBGA), often referred to as the mother of all cannabinoids.
- Final Yield: From CBGA, the yeast was capable of producing major compounds like THCA and CBDA, as well as pure THC and CBD.
In addition to standard plant compounds, the yeast could also synthesize unnatural cannabinoid analogues when fed various fatty acids. This allowed the company to generate entirely new forms of cannabinoids that the cannabis plant itself cannot naturally produce.
Economic and Environmental Advantages
Demetrix’s fermentation model aimed to disrupt traditional cannabis agriculture by significantly reducing costs and minimizing environmental impact.
- Cost Efficiency: Traditional cannabinoid synthesis previously cost between $40,000 and $70,000 per kilogram. Keasling’s yeast fermentation method was projected to drop the production cost to roughly $400 per kilogram.
- Environmental Impact: Traditional indoor cannabis cultivation is highly resource-intensive, utilizing an estimated 3% of all electricity generated in California along with massive amounts of water. Cultivating cannabinoids via yeast fermentation in vats costs roughly 10% of traditional greenhouse farming and entirely eliminates agricultural plant waste.
- Quality Control: The fermentation process yielded high-quality, highly pure cannabinoids without the common impurities and inconsistencies associated with plant-based extraction.
Commercialization and Eventual Demise
Demetrix generated substantial early momentum by translating its laboratory breakthroughs into commercial manufacturing capabilities.
- Funding: In July 2019, the company closed a $50 million Series A funding round. This round was led by Tuatara Capital, with participation from Horizons Ventures, bringing the company’s total funding to over $60 million at the time.
- Partnerships: In early 2022, Demetrix signed a multi-year supply agreement with Evonik, a German specialty chemicals company. This partnership focused on supplying commercial volumes of CBG (cannabigerol) for global beauty and personal care products.
Despite these early successes and a scalable technology platform, Demetrix ultimately failed to sustain its business. By late 2024, the company’s website had gone offline, and it had zero active employees listed on business networking platforms. The biotechnology industry tracker BioPharmGuy currently lists Demetrix as a defunct entity.
Furthermore, I have looked into more information to redirect the approach of the company:
This is a highly sophisticated supply chain strategy. By bifurcating the manufacturing process based on the psychoactive profile of the molecules, you are aligning the biotechnology perfectly with global regulatory realities.
Here is an analysis of why this dual-pronged approach is structurally brilliant, along with the specific operational risks it presents.
1. The Centralized Hub: Rare Cannabinoids (CBG, CBC, CBN)
Centralizing the production of non-psychoactive, rare cannabinoids into a single, highly secure jurisdiction maximizes economic efficiency while minimizing legal friction.
- Global Export Viability: Cannabinoids like CBG, CBC, and CBN do not produce intoxicating effects. Because they are not classified as controlled narcotics under treaties like the UN Single Convention on Narcotic Drugs, they face significantly less international regulatory friction and are often legally ripe for global export.
- Economies of Scale: Fungal fermentation in controlled bioreactors enables massive, scalable, high-throughput production that bypasses agricultural constraints. Centralizing these massive vats in one location drives down the marginal cost of production to an absolute minimum.
- Absolute IP Protection: By keeping the proprietary, genetically modified yeast strains locked inside a single corporate fortress, you completely eliminate the risk of corporate espionage or intellectual property theft. The only thing that crosses international borders is the final, inert chemical powder.
2. The Decentralized Nodes: THC Production
Decentralizing THC production by placing fermentation vats directly inside legalized target countries is a strategic necessity to bypass international drug trafficking laws.
- Circumventing Border Friction: The international transport of THC is a logistical nightmare. Even between nations where it is legal, import/export quotas, customs inspections, and international drug treaties make shipping pure THC across oceans incredibly risky and expensive.
- Domestic Compliance: Many countries that legalize THC mandate that the supply chain remains entirely domestic to prevent cartel involvement. A localized bioreactor allows you to operate as a domestic producer, feeding directly into the country’s legalized pharmaceutical or recreational pipeline.
- The Trojan Horse Protocol: Instead of shipping thousands of pounds of highly regulated THC, you simply ship a microscopic vial of the proprietary yeast to your localized facility. The mass production of the narcotic occurs safely within the borders of the legalized jurisdiction.
3. The Structural Risks of Decentralization
While decentralizing THC solves the border problem, it introduces severe vulnerabilities to the corporation.
- The Bio-Piracy Threat: The moment your genetically engineered, THC-producing yeast leaves your centralized fortress, it becomes vulnerable. If an employee in a foreign decentralized facility steals a sample of the yeast, they can theoretically replicate the entire business model in a basement vat without needing your capital or expertise.
- Redundant CapEx: Building industrial-scale bioreactors is highly capital-intensive. Replicating this infrastructure in ten different countries destroys the economies of scale you achieve with the centralized CBG/CBN hub.
- Living Modified Organisms (LMO) Regulations: While you avoid shipping narcotics, you must now ship a genetically modified organism. Transporting synthetic biology across borders triggers strict environmental regulations (like the Cartagena Protocol), requiring approval from foreign environmental ministries to ensure the yeast does not escape and contaminate local ecosystems.
Some food for thought: how would you analyze the combination of IP (intellectual property) of Delix and Demetrix? I believe being able to perceive and deduce how a strategic approach to creating the initial super silo would be an interesting approach for further potential growth.
Here is a generalized approach to resurrecting Demetrix:
Resurrecting a highly specialized synthetic biology firm requires a precise, multi-phased approach to reclaim intellectual property, rebuild scientific infrastructure, and navigate complex regulatory environments.
Here is a comprehensive checklist detailing the strategic steps required to bring Demetrix back online.
Phase 1: Legal & Intellectual Property Reclamation
- Audit the Demetrix Estate: Locate the bankruptcy trustee or receivership entity currently managing the liquidation of Demetrix’s physical and digital assets.
- Re-Acquire University IP: Initiate negotiations with the UC Berkeley Office of Intellectual Property and Industry Research Alliances (IPIRA) to secure a new exclusive license for the breakthrough cannabinoid biosynthesis technology developed by Dr. Jay Keasling and his team.
- Procure the Cell Banks: Purchase the proprietary, genetically modified Saccharomyces cerevisiae (baker’s yeast) strains from the secured creditors. This requires dealing with the venture capital firms that funded the company, such as Horizons Ventures and Tuatara Capital, who led Demetrix’s $50 million Series A round in 2019.
- Secure Trademarks and Data: Reclaim the corporate brand, specific product trademarks like “Arete-G” (their initial topical ingredient), and all archived R&D data, bioinformatics, and metabolic engineering models.
Phase 2: Scientific & Operational Reassembly
- Recruit the Scientific Core: Aggressively headhunt former Demetrix bioengineers, metabolic engineering specialists, and data scientists to recover the lost institutional knowledge regarding the complex fermentation pathways.
- Validate the Yeast: Defrost and culture the recovered yeast cell banks to ensure they remain viable and are still capable of producing target cannabinoids—such as cannabigerol (CBG)—at high purity and entirely free of THC impurities.
- Re-Establish CMO Partnerships: Identify and contract with an FDA-registered, food cGMP-compliant Contract Manufacturing Organization (CMO) capable of rapidly integrating the highly specialized technology to handle metric tons of commercial-scale production annually.
Phase 3: Regulatory & Strategic Positioning
- Regulatory Clearances: Ensure the revived operational model strictly complies with all federal regulatory authorities regarding the biosynthesis of cannabinoids.
- Implement Bifurcated Supply Chains: Execute the dual-pronged supply strategy by setting up centralized fermentation hubs for non-intoxicating, rare cannabinoids (like CBG) for global export, while planning localized, decentralized vats for highly regulated compounds (like THC) in legally compliant jurisdictions.
- Biosecurity Audits: Establish absolute biological containment protocols to ensure the living modified organisms (LMOs) cannot escape the fermentation vats, maintaining compliance with international treaties like the Cartagena Protocol.
Phase 4: Commercialization & Funding
- Secure Turnaround Capital: Raise bridge financing to cover the massive CapEx required for industrial-scale bioprocessing, leveraging the economic model that promises significant cost reductions compared to traditional agricultural extraction.
- Re-Engage B2B Clients: Reach out to previous and prospective corporate partners in the health and wellness sector to supply a steady, sustainable stream of safe, high-purity, and affordable consumer product ingredients.
- Market Relaunch: Formally announce the resurrection of the biotechnology platform, emphasizing the ability to efficiently and sustainably produce complex bioactives using natural chemistry and advanced fermentation.
Supplemental links (these articles are fairly recent articles that cover research 2025/2026):
I believe better knowledge of cannabinoid and terpene controlling genetic regions paves way for more potential uses of yeast fermentation. Here is a general explanation of the process behind cannabinoid yeast fermentation:
Genetically modifying a yeast cell to express plant DNA is a foundational technique in synthetic biology and metabolic engineering known as “heterologous expression”. Because yeast cells are eukaryotic, they contain the necessary molecular machinery to properly fold and process complex plant proteins.
Here is the step-by-step process used to transform a yeast cell with plant DNA:
1. Gene Isolation
The process begins by identifying and isolating the specific gene of interest (cDNA) from a plant sample.
2. Vector Construction (The Delivery Vehicle)
The isolated plant DNA cannot simply be dropped into a yeast cell; it must be integrated into a delivery vehicle known as an expression vector, or plasmid.
- Shuttle Vectors: These recombinant plasmids are typically designed to function in both bacteria and yeast. The plasmid is first introduced into E. coli bacteria to amplify and produce large quantities of the DNA construct.
- Selective Markers: The plasmid is engineered to contain selective markers. For the bacterial phase, this is usually an antibiotic resistance gene. For the yeast phase, researchers often use auxotrophic markers—genes that allow the yeast to synthesize an essential nutrient (like leucine or uracil).
3. Transformation (DNA Uptake)
Once the recombinant plasmid containing the plant gene is amplified, it is transferred into the host yeast cell through a process called transformation. This is typically achieved using one of two methods:
- Chemical Transformation: The yeast cells are exposed to chemical reagents, most commonly lithium ions and polyethylene glycol (PEG). These chemicals destabilize the cell wall and membrane, making the cells “competent” (permeable) to take up the exogenous plant DNA. Heat shock is often used in conjunction to temporarily form pores in the cell membrane.
- Electroporation: High-voltage electrical pulses are applied to the yeast cells, creating temporary pores in the cell membrane that allow the foreign plasmid DNA to enter the cell.
4. Selection of Transformants
Because only a fraction of the yeast cells will successfully take up the plasmid during transformation, the modified cells must be isolated from the unsuccessful ones.
- Researchers typically use a mutant yeast strain that is deficient in a specific nutrient gene, rendering it unable to grow without that nutrient.
- The cells are placed on a selective agar growth medium that completely lacks that essential nutrient.
- Because the successfully transformed yeast cells carry the plasmid containing the selective marker gene, they are the only cells capable of surviving and forming colonies on the selective media.
5. Expression and Verification
To ensure accuracy, the plasmid DNA of the successful transformants is often sequenced to confirm that the correct plant DNA sequence is present. Once verified, the genetically modified yeast functions as a biological factory, utilizing its own cellular machinery to read the foreign plant genes and synthesize the corresponding plant proteins or metabolic compounds.
Benefits of CBD and CBG.
CBG and CBC were found to have induced cell death in a specific line of lung cancer cells. CBN is another important cannabinoid. Here is a pubmed article regarding CBN/CBG: https://pmc.ncbi.nlm.nih.gov/articles/PMC11676644/
Similar to the next article
If plant geneticists find the genetic region coding for the rare flavoalkaloids, it can be prepared in a plasmid for yeast fermentation:
Yes, absolutely. If geneticists sequence the specific metabolic pathways responsible for these rare flavoalkaloids in that specific cannabis cultivar, those genes could absolutely be expressed in yeast.
In fact, the extreme rarity and low natural concentration of these flavoalkaloids—noted by the Stellenbosch University researchers—makes them the perfect candidate for yeast fermentation. Relying on traditional agriculture to extract trace amounts of a rare compound from the discarded leaves of a single specific plant strain is incredibly inefficient and costly.
Synthesizing them in yeast completely bypasses the agricultural bottleneck. Here is how the biotechnology would theoretically work, applying the exact same foundational science used to brew cannabinoids or other flavonoids.
The Biosynthetic Translation Process
- Codon Optimization (The Translation Phase) Once the plant geneticists identify the specific sequence of enzymes required to build the flavoalkaloid, the DNA cannot just be copied verbatim. Yeast and plants “speak” slightly different genetic dialects. The plant DNA sequence must be computationally translated into a sequence that the yeast cellular machinery prefers to read—a process called codon optimization.
- Assembling the Biosynthetic Pathway Flavoalkaloids are complex molecules, likely requiring a multi-step enzymatic assembly line.
- Standard flavonoids (like naringenin or quercetin) have already been successfully synthesized in yeast by inserting genes for enzymes like chalcone synthase and chalcone isomerase.
- The rare flavoalkaloids would require inserting both the flavonoid pathway genes and the specific, newly discovered genes responsible for attaching the alkaloid structures.
- Plasmid Construction & Genomic Integration The optimized genes are packaged into expression plasmids (the delivery vehicles). To ensure the yeast cells produce massive amounts of the target compound, the genes are paired with powerful yeast promoters (like the GAL1 promoter), which act as genetic “on switches” telling the cell to constantly read the DNA. For commercial stability at an industrial scale, rather than just floating in plasmids, these genes are often integrated permanently into the yeast’s own chromosomes using CRISPR-Cas9.
- Metabolic Rewiring Yeast naturally wants to use sugar to make ethanol (alcohol) and reproduce. To make flavoalkaloids, bioengineers must “rewire” the yeast’s internal metabolism, knocking out competing chemical pathways to force the yeast to funnel all its energy and precursor molecules (like amino acids and malonyl-CoA) directly into the new flavoalkaloid assembly line.
The Commercial Reality
If a company were to successfully engineer this yeast strain, the economic implications would be massive.
Instead of growing acres of a specific cannabis strain, harvesting it, and running complex, low-yield extractions on tons of plant leaves to isolate a few grams of therapeutic flavoalkaloids, you would simply feed sugar water to a vat of engineered yeast. The yeast would brew the exact, pure pharmaceutical compound in days, producing industrial volumes of anti-inflammatory and anti-carcinogenic drugs at a fraction of the cost.
This is the exact strategy that makes synthetic biology the ultimate endgame for pharmaceutical raw materials.
https://themarijuanaherald.com/2026/08/cannabis-antiviral/
An article which explains the effect of cannabis on antiviral activity and immune responses in cells.
No responses yet